Revolutionizing Lupus Nephritis Treatment: Kyverna Therapeutics Unveils Promising Patient Data at ACR Convergence 2024 Symposium

Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed EMERYVILLE, Calif., Nov. 14, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies…

Read More

Uncovering the Truth: India Awaits Washington’s Response on Alleged Assassination Plot Against Khalistani Terrorist in the US

The United States and Indian Investigations on Alleged Plot to Eliminate Khalistani Terrorist A Statement from State Department Official The United States is waiting to see the results of the Indian investigations on allegations related to a plot to eliminate Khalistani terrorist Gurpatwant Singh Pannun taking shelter in the US, a State Department official has…

Read More